Cargando…

HBV Genotype B/C and Response to Lamivudine Therapy: A Systematic Review

A number of nucleoside analogues such as lamivudine (LAM), actually used for the treatment of chronic hepatitis B, can suppress HBV DNA replication, improve transaminase level and liver histology, and enhance the rate of hepatitis B e antigen (HBeAg) clearance. The responses to LAM therapy involve H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xiu-Li, Li, Man, Zhang, Xiao-Lan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863712/ https://www.ncbi.nlm.nih.gov/pubmed/24364035 http://dx.doi.org/10.1155/2013/672614

Ejemplares similares

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China
por: Gu, Lijun, et al.
Publicado: (2015)

A Novel Hydrodynamic Injection Mouse Model of HBV Genotype C for the Study of HBV Biology and the Anti-Viral Activity of Lamivudine
por: Li, Xiumei, et al.
Publicado: (2016)

Molecular epidemical characteristics of Lamivudine resistance mutations of HBV in southern China
por: Li, Si-Yue, et al.
Publicado: (2011)

Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis
por: Luo, Aoran, et al.
Publicado: (2018)

Lamivudine treatment for severe acute HBV hepatitis
por: Lisotti, Andrea, et al.
Publicado: (2008)

Long-Term Hepatitis B Virus (HBV) Response to Lamivudine-Containing Highly Active Antiretroviral Therapy in HIV-HBV Co-Infected Patients in Thailand
por: Khamduang, Woottichai, et al.
Publicado: (2012)

The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy
por: Cai, Qingqing, et al.
Publicado: (2016)

HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy
por: Banerjee, Priyanka, et al.
Publicado: (2017)

The Naturally Occurring YMDD Mutation among Patients Chronically Infected HBV and Untreated with Lamivudine: A Systematic Review and Meta-Analysis
por: Tan, Youwen, et al.
Publicado: (2012)

Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy
por: Costantini, Andrea, et al.
Publicado: (2011)

Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa
por: Stewart, Balint, et al.
Publicado: (2011)

Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
por: Sheng, Yun-Jian, et al.
Publicado: (2011)

Evaluation of adefovir & lamivudine in chronic hepatitis B: Correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis
por: Pradeep, Kumar S, et al.
Publicado: (2011)

Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil
por: Bottecchia, Marcelle, et al.
Publicado: (2008)

Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
por: Kim, Jeong Han, et al.
Publicado: (2013)

Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus
por: Chen, En-Qiang, et al.
Publicado: (2009)

The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis
por: Yang, Jiao, et al.
Publicado: (2016)

Single-virion sequencing of lamivudine-treated HBV populations reveal population evolution dynamics and demographic history
por: Zhu, Yuan O., et al.
Publicado: (2017)

Efficacy of Lamivudine or Entecavir against Virological Rebound after Achieving HBV DNA Negativity in Chronic Hepatitis B Patients
por: Miyauchi, Tomoo, et al.
Publicado: (2013)

Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine
por: Santos, Eneida A, et al.
Publicado: (2004)

Entecavir and lamivudine therapy for severe acute chronic hepatitis B
por: LIU, CHANGHONG, et al.
Publicado: (2013)

Lamivudine Therapy for Korean Children with Chronic Hepatitis B
por: Koh, Hong, et al.
Publicado: (2007)

Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy
por: Wang, Changtai, et al.
Publicado: (2019)

Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients
por: Nakamuta, Makoto, et al.
Publicado: (2007)

Lamivudine and Entecavir for Acute Hepatitis B: A Systematic Review and Meta-Analysis
por: Henriquez-Camacho, Cesar, et al.
Publicado: (2023)

Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review
por: Zhao, Shushan, et al.
Publicado: (2010)

The Importance of Lamivudine Therapy in Liver Cirrhosis Patients Related HBV with Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy
por: Momiyama, Koichi, et al.
Publicado: (2015)

Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy
por: Huang, Meijin, et al.
Publicado: (2019)

Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy
por: Ismail, Sohair, et al.
Publicado: (2014)

Hepatitis B Virus Genotyping Among Chronic Hepatitis B Individuals With Resistance to Lamivudine in Shahrekord, Iran
por: Karimi, Ali, et al.
Publicado: (2014)

Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis
por: Wang, Hui-Lian, et al.
Publicado: (2016)

HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons
por: Bihl, Florian, et al.
Publicado: (2015)

Long-Term Outcomes and Dynamics of Mutants Associated with Lamivudine-Adefovir Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B
por: Kim, Jihyun, et al.
Publicado: (2015)

Characteristics of HBV infection in 705 HIV-infected patients under lamivudine-based antiretroviral treatment from three regions in China
por: Su, Mingze, et al.
Publicado: (2018)

Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine
por: Yasutake, Yoshiaki, et al.
Publicado: (2020)

Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B
por: Chao, Daniel C, et al.
Publicado: (2013)

Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B
por: Shakado, Satoshi, et al.
Publicado: (2008)

Lamivudine therapy for chronic hepatitis B in children: a meta-analysis
por: Luo, Aoran, et al.
Publicado: (2019)

The Impact of HBV Quasispecies Features on Immune Status in HBsAg+/HBsAb+ Patients With HBV Genotype C Using Next-Generation Sequencing
por: Wang, Ying, et al.
Publicado: (2021)

Treatment of Hepatitis B Virus-Associated Membranous Nephropathy: Lamivudine Era versus Post-Lamivudine Era
por: Moon, Ju-Young, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_sfokectu3uhnrhln9tei3vbkbt